These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 146056)
61. Physiological disposition of verapamil in man. Schomerus M; Spiegelhalder B; Stieren B; Eichelbaum M Cardiovasc Res; 1976 Sep; 10(5):605-12. PubMed ID: 971476 [TBL] [Abstract][Full Text] [Related]
62. Ocular pharmacokinetics of thiamphenicol in rabbits. Aldana I; Fos D; Gonzalez Peñas E; Gazzaniga A; Gianesello V; Ceppi Monti N; Figini PG; Zato MA; Bruseghini L; Esteras A Arzneimittelforschung; 1992 Oct; 42(10):1236-9. PubMed ID: 1472144 [TBL] [Abstract][Full Text] [Related]
63. Enhanced systemic tissue distribution after dermal versus intravenous 3,3',4,4'-tetrachlorobiphenyl exposure: limited utility of radiolabel blood area under the curve and excretion data in dermal absorption calculations and tissue exposure assessment. Qiao GL; Riviere JE Toxicol Appl Pharmacol; 2001 Nov; 177(1):26-37. PubMed ID: 11708897 [TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetic Comparison of Once-Daily Topical Minocycline Foam 4% vs Oral Minocycline for Moderate-to-Severe Acne. Jones TM; Ellman H; deVries T J Drugs Dermatol; 2017 Oct; 16(10):1022-1028. PubMed ID: 29036256 [TBL] [Abstract][Full Text] [Related]
65. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man. Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544 [TBL] [Abstract][Full Text] [Related]
66. Absolute bioavailability, pharmacokinetics, renal and biliary clearance of distigmine after a single oral dose in comparison to i.v. administration of 14C-distigmine-bromide in healthy volunteers. Vree TB; Waitzinger J; Hammermaier A; Radhofer-Welte S Int J Clin Pharmacol Ther; 1999 Aug; 37(8):393-403. PubMed ID: 10475142 [TBL] [Abstract][Full Text] [Related]
67. Plasma disposition and faecal excretion of eprinomectin following topical and subcutaneous administration in non-lactating dairy cattle. Aksit D; Korkut O; Aksoz E; Gokbulut C N Z Vet J; 2016 Jul; 64(4):207-11. PubMed ID: 26820168 [TBL] [Abstract][Full Text] [Related]
68. Oral and topical absorption, disposition kinetics, and the metabolic fate of trans-methyl styryl ketone in the male Fischer 344 rat. Sauer JM; Smith RL; Bao J; Kattnig MJ; Kuester RK; McClure TD; Mayersohn M; Sipes IG Drug Metab Dispos; 1997 Jun; 25(6):732-9. PubMed ID: 9193875 [TBL] [Abstract][Full Text] [Related]
69. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Jacobs MR; Appelbaum PC Expert Opin Pharmacother; 2006 Oct; 7(14):1957-66. PubMed ID: 17020421 [TBL] [Abstract][Full Text] [Related]
70. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Setnikar I; Rovati LC Arzneimittelforschung; 2001 Sep; 51(9):699-725. PubMed ID: 11642003 [TBL] [Abstract][Full Text] [Related]
71. Mirex kinetics in the rhesus monkey. I. Disposition and excretion. Wiener M; Pittman KA; Stein V Drug Metab Dispos; 1976; 4(3):281-7. PubMed ID: 6234 [TBL] [Abstract][Full Text] [Related]
72. Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents. Wilhelm KP; Wilhelm D; Neumeister C; Zsolt I; Schwantes U Clin Exp Dermatol; 2012 Mar; 37(2):112-7. PubMed ID: 22103435 [TBL] [Abstract][Full Text] [Related]
73. Disposition and absolute bioavailability of furosemide in healthy males. Waller ES; Hamilton SF; Massarella JW; Sharanevych MA; Smith RV; Yakatan GJ; Doluisio JT J Pharm Sci; 1982 Oct; 71(10):1105-8. PubMed ID: 7143205 [TBL] [Abstract][Full Text] [Related]
74. Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study. Marcinkiewicz J; Wojas-Pelc A; Walczewska M; Lipko-Godlewska S; Jachowicz R; Maciejewska A; Białecka A; Kasprowicz A Eur J Dermatol; 2008; 18(4):433-9. PubMed ID: 18573718 [TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel. Kvaternick V; Kellermann M; Knaus M; Rehbein S; Rosentel J Vet Parasitol; 2014 Apr; 202(1-2):2-9. PubMed ID: 24703069 [TBL] [Abstract][Full Text] [Related]
76. On the bioavailability of topical formulations of clindamycin hydrochloride. Franz TJ J Am Acad Dermatol; 1983 Jul; 9(1):66-73. PubMed ID: 6886106 [TBL] [Abstract][Full Text] [Related]
77. Absorption kinetics of topical clindamycin preparations. Eller MG; Smith RB; Phillips JP Biopharm Drug Dispos; 1989; 10(5):505-12. PubMed ID: 2804254 [TBL] [Abstract][Full Text] [Related]
78. Absorption and elimination of (14C) hesperidin methylchalcone in the rat. Chanal JL; Cousse H; Sicart MT; Bonnaud B; Marignan R Eur J Drug Metab Pharmacokinet; 1981; 6(3):171-7. PubMed ID: 7308237 [TBL] [Abstract][Full Text] [Related]